EP Wealth Advisors LLC Purchases 60 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

EP Wealth Advisors LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 14,787 shares of the medical equipment provider’s stock after acquiring an additional 60 shares during the quarter. EP Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $6,578,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Capital Research Global Investors bought a new position in Intuitive Surgical during the first quarter valued at $374,390,000. Coatue Management LLC grew its position in Intuitive Surgical by 65.7% in the fourth quarter. Coatue Management LLC now owns 1,301,595 shares of the medical equipment provider’s stock worth $439,106,000 after acquiring an additional 516,054 shares in the last quarter. Vanguard Group Inc. increased its stake in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after purchasing an additional 302,382 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Intuitive Surgical by 1.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,414,931.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $438.60, for a total transaction of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 in the last ninety days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $491.27 on Tuesday. The company has a market cap of $174.25 billion, a PE ratio of 88.68, a P/E/G ratio of 5.39 and a beta of 1.39. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $496.18. The firm’s 50 day moving average price is $473.63 and its 200-day moving average price is $429.56.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 earnings per share. On average, analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ISRG. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their target price for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Evercore ISI reduced their target price on shares of Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research note on Friday, July 19th. Piper Sandler raised their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Finally, Robert W. Baird raised their price objective on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.